Lumisight

Lumisight is an IV fluorescent imaging agent used during lumpectomy to highlight residual breast cancer tissue inside the surgical cavity. This real-time tool helps surgeons ensure more complete tumor removal and aims to lower the need for additional surgery.

Molecule Details :

  • Molecule Name :

    Pegulicianine
  • Innovator :

    LUMICELL INC
  • Approval Date :

    17-Apr-24
  • NCE-1 Date :

    17-Apr-28
  • NCE Date :

    17-Apr-29
  • Dosage Form :

    Intravenous Powder Injection
  • Strength :

    EQ 40MG BASE-VIAL
  • Therapeutic Category :

    Diagnostic Agents
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    NA
  • 2026 :

    NA
  • 2027 :

    NA
  • 2028 :

    NA
  • 2029 :

    NA
  • 2030 :

    NA
  • 2031 :

    NA
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?